Provided by Tiger Trade Technology Pte. Ltd.

Immunic, Inc.

16.50
+0.40002.48%
Volume:147.69K
Turnover:2.43M
Market Cap:224.40M
PE:-4.13
High:16.83
Open:16.22
Low:16.20
Close:16.10
52wk High:17.43
52wk Low:5.06
Shares:13.60M
Float Shares:11.92M
Volume Ratio:0.87
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9979
EPS(LYR):-6.2414
ROE:-138.17%
ROA:-66.80%
PB:1.76
PE(LYR):-2.64

Loading ...

Immunic Q1 FY26 net loss widens to $32.6 million

Reuters
·
May 13

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 13

Immunic Inc expected to post a loss of 91 cents a share - Earnings Preview

Reuters
·
May 12

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Hinge Health, Inc. Class A (HNGE)

TIPRANKS
·
May 06

Immunic Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 30

Immunic attends Bio€quity Europe investor conference in May

Reuters
·
Apr 30

Immunic price target adjusted to $22 from $5 at H.C. Wainwright

TIPRANKS
·
Apr 30

Immunic files Form 3 for Chief Medical Officer Michael A. Panzara

Reuters
·
Apr 29

Immunic names Michael Panzara chief medical officer, replacing Andreas Muehler

Reuters
·
Apr 28

BRIEF-Immunic Appoints Biopharmaceutical Executive Michael Panzara As Chief Medical Officer

Reuters
·
Apr 28

Immunic Appoints Accomplished Biopharmaceutical Executive Michael a. Panzara, M.d., M.p.h., as Chief Medical Officer

THOMSON REUTERS
·
Apr 28

Press Release: Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer

Dow Jones
·
Apr 28

Immunic trading halted, news pending

TIPRANKS
·
Apr 25

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM

Reuters
·
Apr 25

Immunic effects 1-for-10 reverse stock split April 27

Reuters
·
Apr 23

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

THOMSON REUTERS
·
Apr 23

Immunic Buy Rating: Vidofludimus Calcium’s Differentiated Efficacy and Safety Profile vs. BTK Inhibitors in Relapsing MS

TIPRANKS
·
Apr 23

Okta, Immunic, FirstEnergy, ADC, GNL Trending With Analysts

TIPRANKS
·
Apr 18

Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says

Benzinga_recent_news
·
Apr 18

Stifel Nicolaus Initiates Coverage on Immunic With Buy Rating, $2.50 Price Target

MT Newswires Live
·
Apr 17